Prof Al-Jamal is an overseas (Jordan) and a UK-registered pharmacist. She completed her PhD in Nanotechnology and Drug Delivery from London School of Pharmacy (now known as UCL School of Pharmacy), following receiving the prestigious Overseas Research Scholarship (ORS) Award from the University of London. Her PhD research project focused on developing novel liposome-based systems for combinatory therapeutic and diagnostic purposes. In 2008, Dr Al-Jamal joined UCL School of Pharmacy as a Research Fellow focusing on live animal imaging and evaluating organ biodistribution of various novel gene and drug delivery vectors. In 2012, she was appointed at The Institute of Pharmaceutical Science, King’s College London as a Senior Research Associate, focusing on evaluating the behaviour and the efficacy of personalised nanomedicines to treat cancer. Dr Al-Jamal joined the University of East Anglia, Norwich, as a Lecturer in Nanomedicine and Drug Delivery (2013-2014), before being awarded a five-year Career Development Fellowship from Prostate Cancer UK, to develop novel nanomedicines targeting metastatic prostate cancer. In August 2017, Dr Al-Jamal joined Queen’s University Belfast School of Pharmacy as a Reader in Nanomedicine and Drug Delivery. In 2023, she was promoted to Professor of Advanced Nanotherapeutics.

Prof Al-Jamal is a Visiting Professor at Guizhou Medical School, Guiyang, China. She was the GSK Emerging Scientist Award winner for 2015 for her work in the field of Cancer Nanomedicine. She also received the prestigious international Gro Brundtland Award, Taiwan, that recognizes distinguished female scientists in the field of sustainable development.

Prof Al-Jamal's multidisciplinary team works on developing novel nanomedicines for combinatory therapy and theranostic applications. Currently, her research focuses on developing smart vectors for delivering a broad range of therapeutic agents, and fabricating multifunctional nanoparticles to target cancer and other diseases. Her long-term research career is to facilitate the translation of nanoparticle-based therapeutics from the lab to the clinic.